Economic burden of chronic obstructive pulmonary disease: A systematic review

Globally, providing evidence on the economic burden of Chronic Obstructive Pulmonary Disease (COPD) is becoming essential to assist health authorities in improving resource allocation. This study aimed to summarize the literature's economic burden evidence for COPD from 1990 to 2019. This study, spanning from 1990 to 2019, examined the economic burden of COPD through a systematic review of online databases, including Web of Science, PubMed/Medline, Scopus, and the Cochrane Library. After meticulous screening of 12,734 studies, 43 articles meeting inclusion criteria were identified. General study information and data on direct, indirect, and intangible costs were extracted and converted to 2018 international dollars (Int$). Findings revealed a range of total direct costs from Int$ 52.08 (India) to Int$ 13,776.33 (Canada) across 16 studies, with drug costs spanning from Int$ 70.07 (Vietnam) to Int$ 8,706.9 (China) in eleven studies. Eight studies explored indirect costs, while one highlighted caregivers' direct costs at approximately Int$ 1,207.8 (Greece). This study underscores the limited research on COPD caregivers' economic burdens, particularly in developing countries, emphasizing the importance of increased research support, particularly in high-resource settings. This study provides information about the cost and demographics of the COPD economic burden from 1990 to 2019. More strategies to reduce the frequency of hospital admissions and acute care services should be implemented to improve COPD patients' lives and control the disease's rising cost and burden.